Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme

Jan Karl Burkhardt, Benjamin J. Shin, Cody D. Schlaff, Howard Riina, John A. Boockvar

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.

Original languageEnglish (US)
Pages (from-to)183-186
Number of pages4
JournalJournal of Experimental Therapeutics and Oncology
Volume9
Issue number3
StatePublished - Dec 29 2011

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Cancer Research

Fingerprint Dive into the research topics of 'Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme'. Together they form a unique fingerprint.

  • Cite this